DRI Healthcare focuses on acquiring and managing pharmaceutical royalty streams, particularly those addressing unmet medical needs in various therapeutic areas.

DRI Healthcare

DRI Healthcare | 3,469 followers on LinkedIn. Advancing science in the fast-growing pharmaceutical and biotechnology sector | DRI Healthcare is a pioneer in global pharmaceutical royalty monetization. Over the course of three decades, we have been a trusted partner of royalty sellers and demonstrated strong execution, building a diversified portfolio of interests in medicines that have a demonstrable positive impact on the world. That foundation sets us apart as we continue developing solutions for innovators while building and managing a risk-mitigated portfolio of therapeutic assets that generates attractive returns and growth potential for investors.

Investing in Biotechnology & Pharmaceuticals

Navin Jacob

Chief Financial Officer | Senior Finance Executive | Trusted Business Partner

Chris Anastasopoulos

Associate General Counsel at DRI Healthcare

Alyssa Klapper

Legal Counsel at DRI Healthcare

Yang (Serena) Li

Yesterday, we announced the acquisition of a synthetic royalty interest in the worldwide sales of sebestralstat for the treatment of hereditary angioedema (“HAE”) plus a private placement in KalVista Pharmaceuticals, Inc. for a total investment of up to US$184 million. If approved, sebetralstat would be the first and only oral on-demand therapy for treating attacks associated with HAE. This is the Trust’s first pre-approval royalty acquisition and first equity investment, highlight our evolving investment strategy. Read more: https://lnkd.in/gpWY7gg9

DRI Healthcare is looking for a Legal Associate to join our team! We are looking for a self-motivated and proactive attorney with corporate and transactional experience. If you or anyone you know is interested in applying, please feel free to reach out or click the link below. https://lnkd.in/gnQhey6Y

Today, we announced the acquisition of a portion of Editas Medicine, Inc.’s payment rights under a non-exclusive license to Vertex Pharmaceuticals Inc. of Editas Medicine’s Cas9 gene-editing technology for CASGEVY® (exagamglogene autotemcel) for an upfront purchase price of US$57 million. This transaction adds another innovative rare disease therapy to our portfolio, and the novel deal structure offers predictable annual cash flows as well as potential additional annual sales-based milestones and a one-time contingent payment. Read more: https://lnkd.in/g-DmcfSk

DRI is looking for a highly motivated and results-driven individual to join our Finance team as a Vice President, Finance. The Vice President, Finance will primarily be responsible for the corporate accounting, reporting, controls and systems related to DRI Capital Inc. If you or anyone you know is interested in applying, please feel free to reach out or click the link below. https://lnkd.in/gnQhey6Y

Today, we announced that DRI Healthcare has agreed to acquire an additional royalty interest in the worldwide sales of Xenpozyme (olipudase alfa) from HLS Therapeutics Inc. for up to US$45.75 million. Xenpozyme is the only product developed and approved for the treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency, also known as Niemann-Pick disease, in pediatric and adult patients. We made our first investment in Xenpozyme in November 2022. Xenpozyme has seen strong sales since it was approved in 2022 and we are excited to increase our exposure to this important treatment. Read more: https://lnkd.in/gJt-J62r

DRI Healthcare would like to welcome Ranee Borgna to the team as Executive Assistant & Office Coordinator.

DRI Healthcare would like to welcome David Jimenez to the team as Analyst, Asset Operations & Analytics.

DRI Healthcare would like to welcome Yang (Serena) Li to the team as Legal Counsel.

We are looking forward to presenting and continuing to advance the Canadian life sciences sector.

DRI is looking for a highly motivated and results driven individual to join our active and growing Investments & Research team as a Senior Analyst. If you or anyone you know is interested in applying, please feel free to reach out or click the link below. https://lnkd.in/gnQhey6Y

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 6, 2024 3:44 PM	8e05c042
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 6, 2024 3:44 PM	48e0ef22
crunchbase trigger	general	Nov 27, 2024 12:50 PM	212a7979
crunchbase profile	general
li profile	general	Nov 6, 2024 3:44 PM	b07a8d5f
translate crunchbase fundingrounds	general
peers	general	Nov 6, 2024 3:44 PM	ccd13f1e
news basic	general	Nov 6, 2024 3:44 PM	f3ee66a9
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

DRIH

COM:DRIHEALTHCARE

DRI Healthcare